List of Excipients in Branded Drug CLOTRIMAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	CLOTRIMAZOLE	clotrimazole	51672-2062	BENZYL ALCOHOL
Sun Pharmaceutical Industries Inc	CLOTRIMAZOLE	clotrimazole	51672-2062	CETOSTEARYL ALCOHOL
Sun Pharmaceutical Industries Inc	CLOTRIMAZOLE	clotrimazole	51672-2062	CETYL ESTERS WAX
Sun Pharmaceutical Industries Inc	CLOTRIMAZOLE	clotrimazole	51672-2062	OCTYLDODECANOL

Generic Drugs Containing CLOTRIMAZOLE

Company	Ingredient	NDC	Excipient
Hikma Pharmacuticals USA USA Inc	clotrimazole	0054-4146	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmacuticals USA USA Inc	clotrimazole	0054-4146	CROSCARMELLOSE SODIUM
Hikma Pharmacuticals USA USA Inc	clotrimazole	0054-4146	DEXTRATES
Hikma Pharmacuticals USA USA Inc	clotrimazole	0054-4146	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CLOTRIMAZOLE?

# Of NDCs	Excipient
1	ALCOHOL
2	AQUA
41	BENZYL ALCOHOL
4	CELLULOSE, MICROCRYSTALLINE

Clotrimazole Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Clotrimazole is a mature, low-cost imidazole antifungal with limited active-ingredient patent leverage in major markets. Commercial opportunity is concentrated in excipient-enabled differentiation: improved residence time, reduced irritation, lower preservative burden, better vaginal retention, convenient topical delivery, pediatric acceptability, and manufacturability.

The strongest opportunities are nonprescription topical and vaginal products, export formulations, combination products, and drug-device systems. A new excipient system is more likely to support market differentiation, regulatory exclusivity, or a formulation patent than to create broad protection around clotrimazole itself.

What is clotrimazole and which dosage forms are commercially relevant?

Clotrimazole is a synthetic imidazole antifungal used against dermatophytes, yeasts, and other susceptible fungi. It is highly lipophilic and practically insoluble in water, which makes formulation performance dependent on particle size, solvent selection, surfactant balance, vehicle structure, and drug release from the dosage form (National Center for Biotechnology Information, 2024).

Dosage form	Typical strength	Main use	Commercial status
Topical cream, lotion, or solution	1%	Tinea infections, candidiasis, superficial fungal infections	Predominantly generic or OTC
Vaginal cream	1% or 2%	Vulvovaginal candidiasis	OTC in the United States under the vaginal antifungal monograph
Vaginal tablet or insert	100 mg, 200 mg, or 500 mg	Vulvovaginal candidiasis	Marketed in multiple international markets
Oral troche or lozenge	10 mg	Oropharyngeal candidiasis	Prescription product in some markets
Powder, spray, or aerosol	Usually 1%	Intertriginous and foot infections	Marketed in selected countries
Combination cream	Varies	Fungal infection with inflammation or bacterial co-infection	Jurisdiction-specific; regulatory scrutiny is higher

Clotrimazole is generally used locally. Systemic exposure is limited in topical and vaginal products, although excipients that increase permeability or damaged-skin penetration can affect exposure and tolerability.

What excipients are most suitable for clotrimazole topical products?

Topical clotrimazole products should balance solubilization, skin deposition, spreadability, drying time, cosmetic acceptability, and antifungal release. A high-solvent formulation may improve initial dissolution but can increase irritation and reduce long-term consumer acceptance.

Cream systems

Oil-in-water creams are the dominant commercial platform because they provide acceptable spreadability and washability. Common functional excipient classes include:

Excipient class	Examples	Primary function	Key development issue
Emollients and oil-phase solvents	Mineral oil, isopropyl myristate, medium-chain triglycerides	Solubilize or disperse clotrimazole; improve skin feel	Excessive oil loading can retard release
Humectants and co-solvents	Propylene glycol, polyethylene glycol, glycerol	Improve wetting and solvent capacity	Irritation risk at high concentrations
Emulsifiers	Polysorbates, sorbitan esters, glyceryl stearate, cetearyl alcohol	Stabilize emulsion	Surfactant level affects release and irritation
Rheology modifiers	Carbomers, xanthan gum, cellulose derivatives	Control viscosity and suspension	May bind drug or alter release
Preservatives	Parabens, phenoxyethanol, benzoic acid systems	Control microbial growth	Preservative sensitivity and regulatory limits
Antioxidants and chelators	Tocopherol, sodium metabisulfite, disodium EDTA	Protect formulation stability	Compatibility with packaging and color stability

A practical development strategy is to compare a conventional emulsion with a lower-water, solvent-rich cream and a structured lipid system. The comparison should measure clotrimazole solubilization, particle-size distribution, in vitro release, skin permeation, evaporation, rheology, and preservative effectiveness.

Gel and hydroalcoholic systems

Gels can deliver faster drying and a less greasy skin feel than creams. Carbomer, hydroxypropyl cellulose, or poloxamer systems may be suitable, but clotrimazole’s water insolubility creates a risk of crystallization during storage.

A gel platform is commercially attractive for scalp, body-fold, and sports-related use. The principal formulation challenge is maintaining a stable molecularly dispersed or finely dispersed drug state without excessive ethanol or propylene glycol. Alcohol-rich systems can sting compromised skin and may be less suitable for pediatric or mucosal use.

Spray, foam, and powder systems

Sprays and foams provide differentiated application for large or hairy areas. Powders can improve moisture control in feet and body folds. These products can support premium positioning through convenience rather than higher pharmacological potency.

The primary technical barriers are dose uniformity, spray pattern, valve compatibility, flammability classification for alcohol-containing products, powder inhalation control, and content uniformity in low-dose actuated systems.

What excipients are most suitable for vaginal clotrimazole products?

Vaginal formulations require longer residence time, controlled release, low irritation, acceptable leakage characteristics, and reliable drug delivery in the presence of vaginal fluid. The strongest commercial opportunity is a formulation that reduces dosing frequency or improves user experience without materially increasing manufacturing complexity.

Vaginal creams

Vaginal creams typically use a water-miscible or emulsion-based vehicle. Propylene glycol, polyethylene glycol, mineral oil, emulsifying waxes, cellulose polymers, and carbomer systems may be used depending on the product design.

Important performance variables include:

• Drug release into simulated vaginal fluid
• Retention on vaginal mucosa
• Leakage after administration
• Applicator dose accuracy
• pH and osmolality
• Microbial limits and preservative performance
• Compatibility with latex and nonlatex condoms
• Local irritation and sensitization

An excipient system that increases mucoadhesion can improve residence time but may delay drug release. The target is not maximum adhesion. It is sufficient retention without a sticky or uncomfortable product.

Vaginal tablets and inserts

Vaginal tablets can provide a lower-mess alternative to creams. Excipients may include lactose, microcrystalline cellulose, starches, povidone, crospovidone, croscarmellose sodium, magnesium stearate, and compression aids, depending on the formulation.

Commercial differentiation can come from:

• Rapid disintegration with sustained local retention
• Lower friability
• Reduced dosing frequency
• Applicator-free insertion
• Low moisture sensitivity
• Improved stability in hot and humid climates
• Smaller tablet size

A major formulation risk is incomplete drug release because clotrimazole is poorly water soluble. Porosity, wetting agents, particle engineering, and hydrophilic matrix design should be optimized together rather than treated as separate variables.

Mucoadhesive and in situ gelling systems

Mucoadhesive polymers such as polycarbophil, carbomer, hydroxypropyl methylcellulose, and selected thiolated polymers can extend local residence. Thermoresponsive poloxamer systems can be designed to become more viscous after administration.

These systems may support formulation patent claims covering polymer concentration ranges, gelation behavior, release profiles, or specific combinations of clotrimazole and excipients. They also create a more demanding regulatory package because local tolerability, microbiological effects, and excipient exposure increase in importance.

What excipients are suitable for clotrimazole troches and lozenges?

Clotrimazole 10 mg troches are designed for slow dissolution in the mouth. The product must maintain local antifungal exposure while minimizing swallowing and gastrointestinal delivery.

Representative excipient functions include:

Function	Potential excipient classes
Structural matrix	Sucrose, mannitol, sorbitol, maltitol
Binding and adhesion	Acacia, povidone, hydroxypropyl cellulose
Lubrication	Magnesium stearate, stearic acid
Flavor and taste masking	Mint, fruit flavors, sweeteners
Saliva interaction	Polyols and hydrophilic binders
Moisture control	Film coatings, low-water processing, protective packaging

The principal commercial weakness of traditional troches is patient adherence. Taste, mouthfeel, dissolution time, dental concerns from sugar, and dosing frequency can reduce use. Sugar-free systems using mannitol, isomalt, xylitol, or compressed polymer matrices may support product differentiation, but polyol-related gastrointestinal effects and compression behavior must be controlled.

An important design target is a predictable dissolution period. A troche that dissolves too quickly may reduce local exposure; one that persists too long may reduce adherence.

What formulation patents could protect clotrimazole products?

Clotrimazole itself is a mature active ingredient, so composition-of-matter protection is generally unavailable for new commercial products. Patent value is more likely to arise from a narrow formulation, delivery system, manufacturing process, or combination.

Formulation patent opportunities

Potential claim categories include:

1. A clotrimazole composition with a defined solvent and surfactant ratio.
2. A crystalline or amorphous clotrimazole dispersion with improved dissolution.
3. A vaginal formulation with defined mucoadhesive polymer content.
4. A controlled-release insert with a specified release profile.
5. A low-irritation formulation with reduced alcohol, propylene glycol, or preservative content.
6. A spray or foam with controlled particle size and deposition.
7. A sugar-free troche with defined dissolution time and hardness.
8. A formulation stable under high-temperature and high-humidity conditions.
9. A combination of clotrimazole with a second active ingredient.
10. A packaging system that limits moisture uptake or improves dose delivery.

Patentability depends on unexpected performance, not simply replacing one conventional excipient with another. A credible formulation patent should link the excipient selection to measurable advantages such as higher drug release, lower crystallization, better mucosal retention, reduced irritation, or improved stability.

Trade-secret protection

Manufacturing process controls may be more valuable than a narrow patent. Examples include:

• Solvent addition order
• High-shear mixing conditions
• Cooling rate
• Particle-size control
• Granulation endpoint
• Deaeration parameters
• Filling temperature
• Homogenization pressure
• Moisture limits for troches and inserts

Trade-secret protection is particularly relevant when the formulation can be designed around without revealing the complete process in a patent.

When does clotrimazole lose exclusivity?

Clotrimazole’s core product exclusivity expired decades ago. In the United States, commercial products are generally governed by generic competition, OTC monograph requirements, or product-specific regulatory approvals rather than an active composition-of-matter patent.

Exclusivity category	Current commercial relevance
Original compound patent	Expired
Original product patent	Expired or commercially immaterial
FDA NCE exclusivity	Expired
Standard topical generic entry	Broadly available
OTC monograph pathway	Relevant for qualifying topical and vaginal products
New formulation patent	Possible, but usually narrow
New drug-device exclusivity	Possible if the product qualifies under a separate regulatory pathway
Pediatric exclusivity	Not a general current barrier for clotrimazole
Biosimilar exclusivity	Not applicable

The commercial question is therefore not whether clotrimazole has broad exclusivity. It is whether a new product can create a defensible niche through formulation performance, branding, distribution, regulatory positioning, or device integration.

What is the Orange Book status of clotrimazole?

The FDA Orange Book is primarily relevant to approved prescription drug products and listed patents submitted by applicants. Topical and vaginal clotrimazole products marketed under OTC frameworks may not provide a meaningful Orange Book patent pathway comparable to a recently approved prescription drug.

For a prescription clotrimazole product, the relevant diligence should include:

• Current Orange Book listing status
• Reference listed drug designation
• Patent certifications
• Approved labeling
• Withdrawal status
• Therapeutic equivalence codes
• Any listed formulation or method-of-use patents

Because clotrimazole products have varied regulatory histories, an Orange Book review should be performed at the specific product and NDA level rather than at the active-ingredient level. FDA Orange Book listings do not establish that every commercial clotrimazole product is protected by an enforceable patent (U.S. Food and Drug Administration, 2024a).

Are there Paragraph IV challenges to clotrimazole products?

Paragraph IV litigation is not a central current market risk for conventional clotrimazole products because the principal active-ingredient and legacy product protections have expired. A Paragraph IV filing could arise if a company launches a newly approved clotrimazole formulation with listed patents.

Potential disputes would likely involve:

• Non-infringement of formulation claims
• Invalidity based on obviousness
• Written-description or enablement challenges
• Patent-term calculations
• Scope of method-of-use claims
• Orange Book listing eligibility
• Regulatory exclusivity tied to a new dosage form

For mature clotrimazole products, the higher-probability competitive risks are ordinary generic substitution, private-label entry, retailer price pressure, and international tender competition.

Which companies are challenging clotrimazole market positions?

The market is fragmented. Competition comes from generic manufacturers, contract manufacturers, OTC brand owners, private-label retailers, and companies selling alternative antifungals.

Relevant competitor categories include:

Competitor category	Examples of competitive products
Generic clotrimazole manufacturers	Creams, vaginal products, troches, tablets
Branded OTC antifungals	Products containing clotrimazole, miconazole, or terbinafine
Prescription dermatology companies	Formulated topical antifungals with differentiated vehicles
Contract development and manufacturing organizations	Ready-to-file creams, gels, inserts, and troches
Retail private labels	Lower-priced 1% creams and vaginal products
Combination-product suppliers	Antifungal-steroid or antifungal-antibacterial products, where permitted

Clotrimazole competes most directly with miconazole for vaginal and topical use and with terbinafine for dermatophyte infections. Terbinafine often has stronger positioning for short-course treatment, while clotrimazole has broad formulation familiarity and low manufacturing cost.

How does clotrimazole compare with miconazole and terbinafine?

Attribute	Clotrimazole	Miconazole	Terbinafine
Therapeutic class	Imidazole	Imidazole	Allylamine
Typical topical strength	1%	2% or 4%, depending on product	1%
Water solubility challenge	High	High	High
Mature generic supply	Extensive	Extensive	Extensive
Vaginal market presence	Strong in many countries	Strong in the United States	Limited
Short-course positioning	Usually weaker	Product-dependent	Stronger for some dermatophyte infections
Excipient differentiation	Creams, inserts, troches, gels	Creams, suppositories, foams	Creams, gels, sprays
Patent opportunity	Narrow formulation claims	Narrow formulation claims	Narrow formulation claims

Clotrimazole’s commercial advantage is platform flexibility. Its weakness is limited pricing power. A successful new product must offer a clear use benefit, such as less frequent dosing, lower mess, faster drying, improved taste, or better tropical-climate stability.

What FDA regulatory pathways apply to clotrimazole products?

OTC products

Topical and vaginal clotrimazole products may qualify under FDA OTC antifungal or vaginal antifungal monograph requirements, depending on dosage form, strength, labeling, active ingredient, and indications. The controlling requirements should be assessed under the current Code of Federal Regulations and FDA monograph framework, including 21 C.F.R. parts 330 and 333 (Electronic Code of Federal Regulations, 2024).

A novel excipient, novel delivery system, new indication, or materially different dosage form may require an NDA rather than monograph compliance.

Prescription products

A prescription product may require an NDA or ANDA pathway depending on the reference product and dosage form. The regulatory burden increases when the product introduces a new route, new strength, new dosage form, or clinically meaningful release modification.

Global markets

Outside the United States, clotrimazole is widely available through national generic, OTC, pharmacy, or traditional medicine pathways. Commercial launch requirements vary by country and may include:

• Local bioequivalence or comparative performance data
• Stability testing under climatic zones
• Excipient acceptability requirements
• Local-language labeling
• Pharmacovigilance systems
• Manufacturing-site inspection
• National reference-product selection

Geographic opportunity is strongest where branded antifungals remain expensive, pharmacy access is high, and tropical conditions increase the prevalence of superficial fungal disease.

What manufacturing and IP barriers affect clotrimazole products?

Clotrimazole is commercially accessible, but manufacturing quality can determine product performance. Key barriers include:

• Maintaining uniform drug dispersion in semisolid products
• Preventing crystallization during storage
• Controlling viscosity across batches
• Achieving reliable vaginal dose delivery
• Managing moisture in troches and vaginal tablets
• Protecting formulations from heat and humidity
• Ensuring compatibility with plastic tubes, applicators, valves, and liners
• Demonstrating preservative effectiveness
• Controlling microbial contamination in water-containing products

Manufacturing know-how can create a practical barrier even where patents are weak. A supplier with validated scale-up, stable emulsification, reproducible particle-size control, and robust packaging may win contracts over a lower-cost competitor.

What commercial opportunities exist for clotrimazole excipient innovation?

Premium OTC dermatology products

A low-grease, fast-drying cream or gel can target consumers who reject conventional antifungal creams. Suitable positioning includes athletic use, body-fold infections, and application under clothing.

Vaginal retention products

A lower-leakage cream, mucoadhesive insert, or once-daily formulation could support premium pricing if clinical or comparative performance data demonstrate a meaningful use advantage.

Sugar-free oral troches

Sugar-free clotrimazole troches could address dental concerns and patient preference. The product would need acceptable taste, controlled dissolution, adequate local exposure, and stable compression performance.

Tropical-climate formulations

Heat- and humidity-stable products have commercial potential in emerging markets. Opportunities include anhydrous creams, moisture-resistant inserts, foil-unit-dose packaging, and formulations with reduced phase separation risk.

Drug-device combinations

Premeasured applicators, metered sprays, dose counters, and applicator-free vaginal inserts can improve dosing reliability and convenience. Device claims may provide additional protection when the formulation alone is difficult to patent.

Combination therapy

Clotrimazole combinations with corticosteroids, antibacterial agents, keratolytics, or barrier-repair ingredients may address specific clinical segments. These products have higher regulatory and safety risk, especially where steroid exposure can mask infection or promote inappropriate use.

How strong is the patent estate for clotrimazole?

The legacy clotrimazole patent estate is weak for broad market exclusion. New protection can be moderate if it covers a technically differentiated formulation with reproducible unexpected results.

Asset type	Estimated commercial strength
Core clotrimazole composition patent	None of practical current value
Conventional 1% cream	Low
Standard vaginal cream or tablet	Low
Novel mucoadhesive or controlled-release system	Moderate if claims are narrow and data-supported
New device plus formulation	Moderate
Manufacturing process	Moderate as trade secret; patent strength depends on detectability
New combination product	Variable
Brand and retail distribution	Potentially strong commercially, but not patent exclusivity

A formulation patent should be supported by comparative evidence against the closest conventional product. Useful evidence includes dissolution, release, crystallization, stability, irritation, retention, and usability data.

What generic launch scenarios exist for new clotrimazole products?

For a conventional product, generic entry is immediate or already established. For a differentiated product, launch risk depends on the regulatory pathway.

Scenario	Likely competitive outcome
Conventional 1% cream	Rapid generic and private-label entry
OTC monograph-compliant product	Low patent protection; competition based on price and distribution
New vaginal insert	Potentially slower entry if device, formulation, or clinical requirements are complex
Prescription extended-release product	ANDA or 505(b)(2) competition may arise after approval
Novel combination product	More substantial regulatory and patent barriers
Drug-device product	Device manufacturing and substitution complexity may slow competition
Export-only product	Local registration and manufacturing economics determine entry speed

The most defensible commercial strategy is usually a portfolio: a low-cost base product for volume, a differentiated vehicle for premium margins, and a device or packaging feature for channel-specific differentiation.

What revenue exposure should investors and licensees evaluate?

Clotrimazole products are generally high-volume, low-price assets. Revenue exposure depends more on market access and channel execution than on patent duration.

Key commercial metrics include:

• Units sold by dosage form
• Net price per treatment course
• Private-label share
• Retail versus prescription mix
• Gross margin after excipient and packaging costs
• Applicator or device cost
• Stability-related write-offs
• Returns from phase separation or leakage
• International tender pricing
• Switching rates from miconazole and terbinafine
• Brand premium over generic equivalents

Licensing value is likely to be highest for an excipient platform that applies to multiple antifungals, not for clotrimazole alone. A mucoadhesive vaginal platform, low-irritation semisolid base, or heat-stable topical vehicle could be licensed across clotrimazole, miconazole, econazole, ketoconazole, and other poorly soluble actives.

Key Takeaways

• Clotrimazole has no meaningful current broad compound exclusivity in major markets.
• Excipient strategy is the main route to product differentiation.
• The strongest technical opportunities are vaginal retention, low-irritation topical delivery, sugar-free troches, and tropical-climate stability.
• Conventional creams and vaginal products face immediate generic and private-label competition.
• Novel formulation patents must rely on specific composition ranges and measurable unexpected performance.
• Manufacturing process control and packaging can create practical barriers where patent protection is weak.
• Licensing a reusable excipient or delivery platform is more attractive than licensing clotrimazole alone.
• Biosimilar risk is irrelevant because clotrimazole is a small-molecule drug.
• Paragraph IV litigation is not a material risk for legacy products but could arise around a newly approved formulation with Orange Book-listed patents.
• Commercial value is driven by convenience, formulation quality, distribution, and manufacturing economics.

FAQs

Can clotrimazole be formulated as a nanosuspension?

Yes. A nanosuspension may improve dissolution and dispersion for poorly water-soluble clotrimazole, but physical stability, particle growth, redispersibility, preservative performance, and scale-up must be demonstrated.

Which excipients can reduce clotrimazole crystallization?

Polymeric stabilizers, surfactants, hydrophilic binders, and selected co-solvents can reduce crystallization. The optimal system depends on whether clotrimazole is molecularly dissolved, amorphous, or suspended.

Is clotrimazole suitable for a once-daily vaginal product?

Potentially. A once-daily product would require adequate local exposure, acceptable retention, controlled release, and tolerability data. A lower dosing frequency could support product differentiation.

Can a new clotrimazole cream receive 30-month regulatory exclusivity?

A conventional OTC cream generally will not receive new-drug exclusivity merely because it uses different excipients. Exclusivity depends on the applicable FDA approval pathway and the nature of the innovation.

Are excipients in clotrimazole products patentable?

Yes, when the excipient combination is tied to a novel and non-obvious composition or technical result. Routine substitutions, conventional concentration adjustments, and predictable vehicle changes are more vulnerable to invalidity challenges.

References

1. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Parts 330 and 333: Over-the-counter human drugs and external analgesic and antifungal drug products. https://www.ecfr.gov/

2. National Center for Biotechnology Information. (2024). PubChem compound summary for clotrimazole. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Clotrimazole

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. U.S. Food and Drug Administration. (2009). Guidance for industry: Pharmaceutical development. https://www.fda.gov/